About GBT
GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its late-stage product candidate, voxelotor (previously called GBT440), for the treatment of sickle cell disease.
